Following on from information provided to NICE by the company in October 2018, the appraisal of Leukaemia (chronic lymphocytic, untreated, TP53-positive) - ibrutinib (with venetoclax and Obinutuzumab) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in October 2018, the appraisal of Leukaemia (chronic lymphocytic, untreated, TP53-positive) - ibrutinib (with venetoclax and Obinutuzumab) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 12 October 2018 | Suspended. The Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia. However, the company have advised that they will not be pursuing a licensing application for venetoclax from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
| 03 August 2017 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual